Experimental and preclinical studies have proven that mTOR is an effective target for colorectal cancer therapy, and considering the close correlation between QSOX2 and mTOR, QSOX2 also may provide promising perspectives for CRC therapy. This evidence concerns the gene MTOR and colorectal carcinoma.